Publikationen in Zusammenarbeit mit Forschern von Institute of Oncology Ljubljana (14)

2024

  1. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study

    The Lancet Oncology, Vol. 25, Núm. 1, pp. 46-61

  2. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

    The Lancet Oncology, Vol. 25, Núm. 1, pp. 29-45

2023

  1. Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma

    European Urology Open Science

2022

  1. Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (Breast Cancer Research and Treatment, (2021), 189, 3, (689-699), 10.1007/s10549-021-06334-0)

    Breast Cancer Research and Treatment

2021

  1. Characteristics of adult patients with chronic intestinal failure due to short bowel syndrome: An international multicenter survey

    Clinical Nutrition ESPEN, Vol. 45, pp. 433-441

  2. Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population

    Breast Cancer Research and Treatment, Vol. 189, Núm. 3, pp. 689-699

  3. Primary cutaneous peripheral T-cell lymphoma, not otherwise specified: results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico-pathological and prognostic features

    Journal of the European Academy of Dermatology and Venereology, Vol. 35, Núm. 3, pp. 658-668

2020

  1. Home parenteral nutrition provision modalities for chronic intestinal failure in adult patients: An international survey

    Clinical Nutrition, Vol. 39, Núm. 2, pp. 585-591

  2. Intravenous supplementation type and volume are associated with 1-year outcome and major complications in patients with chronic intestinal failure

    Gut, Vol. 69, Núm. 10, pp. 1787-1795

2018

  1. Clinical classification of adult patients with chronic intestinal failure due to benign disease: An international multicenter cross-sectional survey

    Clinical Nutrition, Vol. 37, Núm. 2, pp. 728-738

2015

  1. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial

    The Lancet Oncology, Vol. 16, Núm. 7, pp. 763-774

2013

  1. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer

    Journal of Clinical Oncology, Vol. 31, Núm. 20, pp. 2586-2592

  2. The evolving landscape of protein kinases in breast cancer: Clinical implications

    Cancer Treatment Reviews, Vol. 39, Núm. 1, pp. 68-76

2011

  1. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs

    Journal of Clinical Oncology, Vol. 29, Núm. 18, pp. 2543-2549